Abstract:Objective To evaluate the clinical results of treatment for osteosarcoma of the extremities with adjuvant chemotherapy regimen Methods Sixty seven patients with ⅡB extremity osteosarcoma were treated with the combination of adjuvant chemotherapy regimen and definitive surgery Forty seven of them were male and twenty four were female The mean age of the patients at the time of diagnosis was 20 years (ranged 10～51 years) Sixty four lesions involved the lower extremity, with 45 involving the distal femur, 14 the upper tibia, 3 the upper fibula and 2 the proximal femur; Three involved the upper end of the humerus The study of subtype of osteosarcoma revealed that 51 were osteoblastic, 6 chondroblastic, 5 fibroblastic and 5 the other subtypes The patients were divided into three groups according to the adjuvant chemotherapy regimen given, the first group consisted of 23 cases, who were treated with the combination of the presurgical cisplatin hyperthermic isolated limb perfusion (CDP-HILP) and postoperative chemotherapy; the second group of 20 cases, who were treated with the combination of the presurgical CBP-HILP and postoperative chemotherapy; and the other 24 cases were treated with postoperative chemotherapy alone Twenty nine of the 67 patients treated surgically had limb salvage procedures; 35 had amputations and 3 had Tikhoff-Limbergs surgery Multiple histologic sections were procured and examined from each of the surgical specimens in the patients who were treated with preoperative HILP to determine the effect of chemotherapy All patients were followed from 3 to 9 years, and the data were statistically analeyed using SPSS 7 0 Results Among 67 cases, 41 (61 19%) had relapse free survival(RFS) in 2 years after surgery, 37 (55 22%) had RFS in 3 years after surgery, and RFS probability at 5 years after surgery was 49 56% Log-rank analysis showed no significant difference in RFS probability among the three groups(P=0 517 1), but there was a significant difference in RFS probability between patients who had limb salvage procedure and those had amputation(P=0 009 7) Age, sex, site and subtype were not significant prognostic variables in this group of patients Correction analysis revealed that the RFS probability were not related with the rate of the tumor necrosis (P=0 058) Conclusion The data revealed that 1) The chemotherapy regimen mainly including platinic drugs was effective treatment for osteosarcoma ,and was more simple and less expensive than any previous reported chemotherapy for steosarcoma, 2) CDP of chemotherapy regimen for osteosarcoma, which had more nephritic and audio toxicity could be replaced by CBP , And 3)Whether the preoperative chemotherapy is suitable for the patients in whom amputation is inevitable (based on age ,size, and involvement of local structure) remains unclear

Comparison of Pirarubicin-Based Versus Gemcitabine–docetaxel Chemotherapy for Relapsed and Refractory Osteosarcoma: a Single Institution Experience

Evaluation of Pirarubicin–cisplatin Chemotherapy in the Treatment for Refractory and Recurrent High-Grade Osteosarcoma: Experience of a Single Institute

Comparison of Pemetrexed Plus Cisplatin with Gemcitabine Plus Docetaxel in Refractory/metastatic Osteosarcoma: Clinical Outcomes from a Retrospective Database Monitored in a Single Institute

Pirarubicin-based Chemotherapy Displayed Better Clinical Outcomes and Lower Toxicity Than Did Doxorubicin-Based Chemotherapy in the Treatment of Non-Metastatic Extremity Osteosarcoma.

Clinical observation of gemcitabine in combination with docetaxel in patients with recurrent or refractory osteosarcoma

Combination of Gemcitabine and Docetaxel: a Regimen Overestimated in Refractory Metastatic Osteosarcoma?

Efficacy and Safety of Gemcitabine-Docetaxel Combination Therapy for Recurrent or Refractory High-Grade Osteosarcoma in China: a Retrospective Study of 18 Patients.

The assessment of the effectiveness of the adjuvant chemotherapy regimen for the treatment of osteosarcoma

Pirarubicin Versus Doxorubicin in Neoadjuvant/adjuvant Chemotherapy for Stage IIB Limb High-Grade Osteosarcoma: Does the Analog Matter?

Clinical Observation of Gemcitabine Combined with Docetaxel in the Treatment of Ad-Vanced Recurrent and Metastatic Osteosarcoma

Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.

Continuous-infusion Ifosfamide and Doxorubicin Combination As Second-Line Chemotherapy for Recurrent or Refractory Osteosarcoma Patients in China: a Retrospective Study

Apatinib Plus Ifosfamide and Etoposide (IE) Versus IE Chemotherapy Alone for Relapsed or Refractory Osteosarcoma.

Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma

Therapeutic Effect of Pirarubicin-Based Chemotherapy for Osteosarcoma Patients with Lung Metastasis

Apatinib Plus Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma: A Retrospective Study in Two Centres

The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: A systematic review and pre‐clinical study

A retrospective observational study on cases of osteosarcomas treated with a multitherapy: The rationale and effectiveness

Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, Mfolfirinox and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution

Clinical therapeutic efficacy analysis of the optimized neo-adjuvant chemotherapy protocols in the treatment of osteosarcoma

The Open, Multicenters, Double-Arms, Randomized, Parallel Controlled Clinical Trial of Lobaplatin or Gemcitabine Combined with Docetaxel As Second-Line Therapy for Advanced Osteosarcoma-the Effectiveness and Safety Analysis.